Completes Patient Enrollment

Related by string. * completes . complete . COMPLETES . COMPLETE : READ COMPLETE ARTICLE . Complete Idiot Guide . Complete Response Letter . Complete Response letter / PATIENTS . PATIENT . Patients : Breast Cancer Patients . terminally ill patients . Patient Safety / Enrollments . ENROLLMENT . enrollments : Enrollment Rx . Defense Enrollment Eligibility . Concurrent Enrollment * *

Related by context. All words. (Click for frequent words.) 90 Initiates Phase II 90 Completes Enrollment 89 Initiates Enrollment 89 Receives Orphan Drug Designation 89 Meets Primary Endpoint 88 Initiates Clinical Trial 88 Initiates Phase III 88 Presents Positive 87 Files IND 87 Submits NDA 86 Presents Preclinical Data 86 Initiates Clinical 85 Phase 2b Clinical Trial 85 Initiates Phase 85 Receives Milestone Payment 85 Begins Dosing 85 Receives Approvable Letter 85 Commences Phase 85 Drug Candidate 84 Demonstrates Significant 84 Successfully Completes Phase 84 Clinical Trial Results 84 Presents Preclinical 84 Submits Biologics License Application 84 Licenses Novel 84 Patient Enrollment 84 Present Preclinical Data 83 Enrolls First 83 Achieves Primary Endpoint 83 Initiates Dosing 83 Announce License Agreement 83 FDA Accepts 83 Phase III Clinical Trial 83 FDA Clears 83 Completes Dosing 83 Study Evaluating 83 Pivotal Phase III 83 Initiates Clinical Trials 83 Announces FDA Clearance 83 Submits Response 83 Reports Preclinical Data 83 Initiate Phase 82 Demonstrates Positive 82 Receives Orphan Drug 82 Phase IIb Clinical Trial 82 Granted Orphan Drug 82 Earns Milestone Payment 82 Combination REOLYSIN R 82 Phase IIb Trial 82 Therapeutic Competitors Companies 82 Phase 2a Trial 82 Phase 2b Trial 82 Pivotal Phase 82 Submits IND 82 Gets FDA Clearance 82 Collaborators Present 82 Drug Fails 82 Phase III Trial 82 First Patient Enrolled 82 PRN FDA Approves 82 Initiates Phase 2b 82 Novel Oral 82 Receives Fast Track 82 Announces Tentative Approval 82 BioSante Pharmaceuticals Announces 82 Files Investigational 81 Receives FDA Clearance 81 Announces Initiation 81 Initiate Phase III 81 Investigational Compound 81 JAK2 Inhibitor 81 Trial Evaluating 81 Oral Calcitonin 81 Prolongs Survival 81 Presents Positive Preclinical 81 Announces Poster Presentations 81 Reveals Positive 81 Preclinical Data 81 FDA Okays 81 Improves Survival 81 Mylan Receives Approval 80 Drug Shows Promise 80 Hsp# Inhibitor 80 Pivotal Study 80 NDA Submission 80 FDA Approvals 80 pralatrexate injection folate analogue 80 Shows Promising 80 Investigational Oral 80 Tezampanel 80 Receives Complete Response 80 Therapeutic Competitors companiesandmarkets.com adEgemonye 80 Patients Treated With 80 Launches Generic Version 80 Lung Cancer Drug 80 Commence Phase 80 Inc Therapeutic Competitors 80 Receive Milestone Payment 80 Announces Publication 79 Shows Efficacy 79 Vaccine Adjuvant 79 Initiate Clinical Trial 79 Shows Promise Against 79 Develop Novel 79 Clinical Trial Evaluating 79 Announces Presentation 79 Announce Initiation 79 Demonstrates Potential 79 Announce Collaboration Agreement 79 IND Application 79 Previously Treated 79 Xcytrin R 79 Phase 2a Clinical Trial 79 Taro Receives 79 Vitrasert R 79 Phase 1b Clinical Trial 79 Milestone Payment 79 Adjuvant Treatment 79 Pivotal Trial 79 Significantly Improves 79 Investigational Treatment 79 Randomized Phase 79 Submits Supplemental 79 Antitumor Activity 79 Lupus Drug 79 Sign Licensing Agreement 79 Telik logo TELINTRA 79 Receives Positive Opinion 79 Phase III Pivotal 78 Cites Positive 78 Single Dose 78 Immunomedics Announces 78 Spectrum Pharmaceuticals Announces 78 R lenalidomide 78 Pooled Analysis 78 Announces License Agreement 78 Crofelemer budesonide foam 78 Transdermal Patch 78 R MSCRAMM 78 Phase IIa Clinical Trial 78 Receives NASDAQ 78 Oral Fingolimod 78 Gout Drug 78 Preclinical Study 78 Improves Outcomes 78 Anti Tumor 78 Completes Patient Enrolment 78 platform HDL Mimetic 78 Arthritis Drug 78 initiated Phase Ib 78 Teva Provides Update 78 Inc. Nasdaq OXGN 78 IND Filing 78 Sangamo BioSciences Announces 78 Receives Tentative Approval 78 Receives CE Marking 78 Announce Merger Agreement 78 Announce Licensing Agreement 78 FDA Approves 78 Sign License Agreement 78 Kinase Inhibitor 78 Advanced Melanoma 78 Confirmatory Phase 78 First Patient Treated 78 Migraine Drug 78 Severe Sepsis 78 IG HCR ;) CO 78 Patent Covering 77 FDA APPROVES 77 Antibody Drug Conjugate 77 Dose Ranging Study 77 Osteoporosis Drug 77 Announces Licensing Agreement 77 Anti Tumor Activity 77 Submits Application 77 Epilepsy Drug 77 Prostate Cancer Vaccine 77 Reports Positive 77 Identifies Potential 77 Announces Dosing 77 Files Shelf Registration Statement 77 First Patient Dosed 77 Announces Positive 77 Personalized Immunotherapy 77 Begins Shipment 77 candidates Azedra TM 77 Rheumatoid Arthritis Drug 77 Study Demonstrates 77 Systemic Delivery 77 FOLOTYN ® 77 Nasdaq XTLB 77 Abstract Accepted 77 Collaborators Publish 77 Hormone Refractory Prostate Cancer 77 Shows Promise 77 Protease Inhibitor 77 Receives Favorable 77 Files Patent Application 77 Multiple Ascending Dose 77 II Clinical Trial 77 Provides Update Regarding 77 Treatment Naïve 77 TRANSDUR ™ 77 Tyrosine Kinase Inhibitor 77 Sinks Lower 77 Generic Version 77 Jumps Higher 77 Patients Enrolled 77 Reduces Risk 76 Small Molecule 76 Biogen Genentech 76 Pivotal Clinical Trial 76 Randomized Phase II 76 Adjunctive Therapy 76 Announces Successful Completion 76 vapreotide acetate 76 Combination Treatment 76 Mg Usa 76 XL# anticancer compounds 76 Fast Track Status 76 Randomized Double Blind 76 Cholesterol Lowering Drug 76 Receives SFDA Approval 76 Study Showed 76 dependent kinase inhibitor 76 Milestone Payment From 76 Reacquires 76 novel orally inhaled 76 Demonstrates Sustained 76 TM Aganocide 76 Announces Favorable 76 Effectively Treats 76 Namenda Memantine HCl 76 Brentuximab Vedotin SGN 76 Refractory Hodgkin Lymphoma 76 TELINTRA R 76 Patent Issued 76 Awarded Qualifying Therapeutic 76 Significantly Reduces 76 CysDisplay R 76 Psoriasis Drug 76 pharmacogenomic translational research 76 TRANSDUR ® 76 RNAi Therapeutic 76 Receives Patent 76 Shows Statistically Significant 76 Dose Escalation 76 Confirms Efficacy 76 Nicotine Vaccine 76 AAG geldanamycin analog 76 VIVUS Announces 76 markets COLAZAL 76 Amends Agreement 76 TRACON Pharmaceuticals 76 Flamel Technologies Announces 76 HCV Protease Inhibitor 76 Pharma Merck Serono 76 Vicriviroc 76 markets HP Acthar 76 JAK Inhibitor 76 Demonstrates Efficacy 75 Generic Versions 75 Phase 2b Study 75 Agonist MABA program 75 Therapeutic Antibody 75 lead molecular radiotherapeutic 75 Blood Pressure Drug 75 SPRYCEL ® 75 Inc. www.micromet inc.com 75 Novel Antibiotic 75 LymphoStat B TM 75 Topline Results 75 Cypher Sirolimus 75 Biomarker Study 75 MKC# MT 75 Clinical Study Shows 75 Aeolus Pharmaceuticals Announces 75 Q1 Loss Narrows 75 Expanded Indication 75 ATRA IV 75 TO AVOID PREGNANCY WHILE 75 Regains NASDAQ 75 Metastatic Melanoma 75 CYT# potent vascular disrupting 75 Hematological Malignancies 75 oncolytic virus therapies 75 acetonide FA 75 Investigational Drug 75 Q2 Loss Narrows 75 Recombinant Human 75 Schizophrenia Drug 75 Second Pivotal Phase 75 Complicated Skin 75 developing Bicifadine serotonin 75 INSPIRE Trial Phase III 75 Desvenlafaxine Succinate 75 Board Authorizes 75 By JENNIFER LEARN 75 product platforms AZX# 75 REG1 Anticoagulation System 75 Q3 Loss Narrows 75 Supplemental Biologics License Application 75 non nucleoside inhibitor 75 Q3 Loss Widens 75 Long Term Efficacy 75 Demonstrates Potent 75 Introduces Novel 75 evaluating picoplatin 75 Extends Collaboration 75 Survival Benefit 75 Dose Ranging 75 Milestone Payments 75 Anticancer Activity 75 Inhaled Insulin 75 Humanized Anti 75 Cholesterol Drug 75 Q4 Loss Narrows 75 Efficacy Results 75 Double Blind Placebo 75 Slow Progression 75 candidates Azedra 75 Clinical Trial Data 75 highly purified pasteurized 75 TKB# 75 By JAMAAL ABDUL 75 Therapeutic Competitors 75 Pivotal Trials 75 please visit http:/www.vandapharma.com 75 developing ACAPODENE 75 Disease Modifying 75 Commences Phase III 75 Well Tolerated 75 Treatment Resistant 75 Anticancer Drug 75 Immunotherapeutic 75 Vaccine Protects Against 75 Settle Patent Litigation 75 Diabetic Foot Ulcer 75 refractory chronic lymphocytic 75 PPD Declares 75 Orally Active 75 Achieves Milestone 75 Molecular Diagnostic Test 74 Merck OSI Pharmaceuticals 74 Taglich Brothers Initiates Coverage 74 Begins Clinical Trial 74 Nasdaq VNDA 74 Alvine Pharmaceuticals 74 approved incretin mimetic 74 MEK Inhibitor 74 DARA logo 74 please visit http:/www.atherogenics.com 74 FOLFOX6 chemotherapy regimen 74 Initiated Phase 74 Pharmacyclics Announces 74 Sapacitabine 74 HDAC Inhibitor 74 CD# CEA 74 Mg Uk 74 Invites Investors 74 estrogen receptor beta agonist 74 Therapeutic Competitors Report 74 candidate XP# 74 Chronic Hepatitis C 74 Drug Combo 74 ELADUR ™ 74 Phase III Trials 74 Lowers Risk 74 SPL# Gel vaginal microbicide 74 Issued Patent 74 Relapsed Multiple Myeloma 74 Patients Treated 74 Q2 Loss Widens 74 novel emulsion formulation 74 evaluating bafetinib 74 Monoclonal Antibody 74 Successfully Treats 74 Telik Announces 74 R roscovitine CDK cyclin 74 SABER ™ 74 lexidronam injection 74 4SC AG ISIN DE# 74 RANK Ligand inhibitor 74 HER2 Positive 74 COLAZAL R 74 Nasdaq HALO 74 Nasdaq MNKD focuses 74 Receives Positive 74 topical antifungal product 74 Improved Survival 74 Pegloticase 74 sarcoma melanoma 74 Proves Effective 74 Receives Clearance 74 Nasdaq EPCT 74 Patient Treated 74 pentadentate logo R 74 recurrent metastatic ovarian cancer 74 R Saizen R 74 includes TOLAMBA TM 74 VentiRx Pharmaceuticals 74 Vascular Disrupting Agent 74 molecular imaging radiopharmaceutical 74 Parathyroid Hormone 74 hyaluronidase enzyme 74 Genentech sanofi aventis 74 Elagolix 74 Licenses Patents 74 Treatment Reduces 74 Data Suggest 74 Newly Diagnosed Multiple Myeloma 74 Patients Receiving 74 Prospective Randomized 74 methylnaltrexone bromide 74 Statistically Significant 74 signal detection CTSD 74 agonistic human 74 Diabetic Neuropathy 74 interferon gamma 1b 74 NASDAQ MNKD focuses 74 R memantine HCl 74 GVAX ® 74 MKC# 74 Genentech Wyeth Pharmaceuticals 74 Signs License Agreement 74 Renal Cell Carcinoma 74 evaluating tivozanib 74 Fungal Infections 74 Aztreonam Lysine 74 oral prodrug 74 Release Capsules 74 MBRX 74 Testosterone MDTS ® 74 Mouse Model 74 Aradigm Logo 74 Develops Novel 74 Q4 Loss Widens 74 Intravitreal 74 Colaris Colaris AP 74 SinuNase TM 74 Demonstrates Statistically Significant 74 Treatment Experienced 74 Obtains Exclusive License 74 Previously Untreated 74 albiglutide 74 Randomized Double blind 74 novel VDA molecule 74 Amigal TM 74 Anti CD# Antibody 74 Aflibercept 74 Awarded Patent 74 Awarded Patents 74 Nasdaq PARD 74 Safinamide 74 Dose Finding 74 STERIS Corporation Announces 74 Nuvelo Announces 74 Phase III Clinical Trials 74 Empatic ™ 74 Receives Conditional 74 PROVENGE ® 74 Slows Progression 74 Vascular Inflammation 74 VIVITROL ® 73 Adjuvant Chemotherapy 73 pan histone deacetylase 73 Treatment Shows Promise 73 Therapeutic Vaccine 73 developing ostarine selective 73 Bullish Average Crossover 73 visit http:/www.mannkindcorp.com 73 Xeloda ® 73 NOTE POSIDUR ™ 73 Lupus Nephritis 73 Romiplostim 73 Patient Enrolment 73 Successfully Treated 73 Announces Issuance 73 Boehringer Ingelheim MedImmune 73 Regeneron Pharma 73 virus HCV protease inhibitor 73 topical gel formulation 73 Luveris R Ovidrel R 73 Strengthens Balance Sheet 73 Controlled Study 73 Non Invasive Treatment 73 Proven Effective 73 visit www.genenews.com 73 Nasdaq CTIC 73 Submits Investigational 73 MCSP respectively 73 lintuzumab SGN 73 LymphoStat B belimumab 73 AUDIO PROVIDED BY 73 please visit www.abraxane.com 73 Metastatic Colorectal Cancer 73 Terminate Merger Agreement 73 Significantly Increases 73 Potent Antiviral Activity 73 Pruvel TM 73 FDA Approves Generic 73 Completes Tender Offer 73 novel proprietary KL4 73 Medoxomil 73 Relapsing Multiple Sclerosis 73 Appears Safe 73 Commercialize Novel 73 Million Milestone Payment 73 RNAi Therapeutics 73 Multicenter Phase 73 IIa Clinical Trial 73 Ovitrelle R Serostim 73 markets Testim ® 73 Study Shows Benefits 73 MOVIPREP R 73 J Am Coll 73 Preclinical Models 73 investigational oral inhibitor 73 Pafuramidine 73 combines bupropion 73 Pulmonary Arterial Hypertension 73 Patients Suffering 73 PHRM 73 Announces Stockholder Approval 73 Acute Attacks 73 NASDAQ MIPI 73 Phase Ib Clinical Trial 73 Receives CE 73 Obtains FDA 73 AVI BioPharma Announces 73 Oral Laquinimod 73 Expand Collaboration 73 Lanthanum Carbonate 73 Significantly Improved 73 Polymerase Inhibitor 73 Welcomes Analyst Initiation 73 Commercializes 73 memantine HCl 73 Inc. Nasdaq IMGN 73 Am J Obstet 73 Eluting Stent 73 Initiate Phase II 73 Successfully Completes Tender Offer 73 Sagent Pharmaceuticals Announces 73 OTC BB PVCT 73 Q1 Loss Widens 73 2 methoxyestradiol 73 Glufosfamide 73 Plaque Psoriasis 73 Receives Unsolicited 73 orally administered inhibitor 73 Telaprevir VX 73 Nasdaq AEGR 73 candidate deforolimus 73 Testosterone Gel 73 PF # [002] 73 Investigational Agent 73 Perifosine KRX 73 Gentium Announces 73 Regains Compliance 73 Test Detects 73 includes Dideco CarboMedics 73 Revises FY# Outlook 73 Veronate R 73 Tumor Targeting 73 Bone Metastases 73 delivery polymer matrix 73 Peginterferon alfa 2b 73 Crit Rev 73 hypoxia activated prodrug 73 dihydrochloride Tablets 73 Announces Immediate Availability 73 Pharmacokinetic Study 73 IL# PE#QQR 73 Therapy Improves 73 Prostate Cancer Patients 73 Enters Into Licensing Agreement 73 ELADUR TM 73 Monotherapy 73 Merck Serono Nycomed 73 Signs Licensing Agreement 73 Romidepsin 73 Settles Litigation 73 Novel Therapeutic 73 PDUFA Date 73 Obtains Approval 73 Recommends Approval 73 Demonstrated Significant 73 Treatment Naive Patients 73 Hematology Molecular Pathology 73 CNS Disorders 73 Interferon Alpha 73 Kaydon Corporation Announces 73 Receives Notification 73 NASH Huntington 73 Inc. NASDAQ QLTI 73 Glatiramer Acetate 73 Updates Guidance 73 Levels Linked 73 drug pipeline TAFA# 73 Levoleucovorin 73 Nasdaq PGNX 73 evaluating mipomersen 73 Low Dose 73 Phase #b/#a clinical 73 humanized therapeutic 73 Preclinical Efficacy 73 Announces Adjournment 73 initiated Phase 1b 73 Prochymal TM 73 Novel Inhibitor 73 Bearish Speculation 73 GATTEX TM 73 Hypertensive Patients 73 Nasdaq AVNC 73 Vitrasert ® 73 Factor Receptor 73 NicVAX TM 73 Rotavirus Vaccine 73 Treating Chronic 73 dasatinib Sprycel ® 73 Unsolicited Proposal From 73 FDA Approves Drug 73 topically applied SEPA 73 KRYSTEXXA TM pegloticase 73 Bosutinib 73 Atripla combines 73 Board Unanimously Rejects 72 successfully commercialize Iluvien 72 Acquires Exclusive 72 including eniluracil ADH 72 Announces Dismissal 72 Successful Completion 72 Expands Scientific Advisory 72 Vaccine Candidate 72 investigational humanized monoclonal antibody 72 Receives Tentative FDA 72 5q MDS 72 ODT metoclopramide HCl PEPCID 72 PROMUS R 72 Hedgehog Pathway Inhibitor 72 Showed Significant 72 Completes Previously Announced 72 Zorbtive TM 72 Net Loss Narrows 72 NICE Recommends 72 PNP inhibitor 72 Inc. OTCBB ECTE 72 Restructures Operations 72 Pharmaceuticals Initiates 72 AnaSpec Introduces 72 oral nucleoside analogue 72 Hydrochlorothiazide Tablets 72 telomerase therapeutic 72 Canaccord Genuity Maintains Hold 72 Aloxi ® 72 Predict Risk 72 Announces Discontinuation 72 Transcept Pharmaceuticals 72 BioElectronics Announces 72 Attenuates 72 ORADUR ® 72 ALN HPN 72 Bullish Technical Alert 72 Genotyping Test 72 developing Zerenex ferric 72 R famotidine 72 Key Milestones 72 Voluntarily Withdraw 72 Microwave Ablation System 72 sapropterin dihydrochloride 72 Announce Definitive Agreement 72 Oral Formulation 72 Hematological Cancers 72 Aurora Kinase 72 Exherin 72 Novel Compound 72 Boxed Warnings 72 BCG refractory carcinoma 72 Is Well Tolerated 72 brand ciclesonide HFA 72 Settle Patent Dispute 72 ® lenalidomide 72 Randomized Trials 72 Regains Compliance With 72 orally inhaled migraine 72 Vitro Activity 72 Therapeutic Efficacy 72 Positive Opinion 72 Novartis Novo Nordisk 72 Restructures Debt 72 rasagiline tablets 72 Bradmer Pharmaceuticals 72 Treated Patients 72 Inc. NASDAQ VSGN 72 Randomized Clinical Trials 72 Anticancer Compound 72 ARRY # 72 Solazed TM 72 Randomized Study 72 TNF Blockers 72 product candidate Lpathomab 72 Further Validates 72 Friedreich Ataxia FRDA 72 Subtypes 72 ALN PCS 72 subsidiaries visit http:/www.apricusbio.com 72 BiovaxID TM 72 Ecallantide 72 humanized interleukin 6 72 Gene Linked 72 SIX RO ROG 72 Secures Financing 72 markets XIFAXAN ® 72 Testosterone MDTS R 72 proprietary intranasal insulin 72 TriCo Bancshares Announces 72 Matrix Phase 2b 72 sanofi aventis Bayer Schering 72 Derma Sciences Announces 72 Tramiprosate ALZHEMED TM 72 Staphylococcus aureus Immune Globulin 72 LifeVantage Announces 72 novel synthetic PEGylated 72 Elderly Patients 72 Bucindolol 72 Selective Electrochemical Tumor Ablation 72 dextromethorphan quinidine 72 Orphan Status 72 corticotropin injection 72 Cutaneous T 72 DepoCyt ® Abelcet ® 72 Signs Merger Agreement 72 Node Positive 72 Combination Therapy 72 Grants Orphan Drug 72 Albuferon TM 72 Diamyd Medical Diamyd 72 peptidic compound 72 Takeda Kyowa Hakko Kirin 72 Benign Prostatic Hyperplasia 72 Statin Drugs 72 Resubmission 72 Backs FY# Outlook 72 Myriad logo BRACAnalysis 72 delivers fluocinolone acetonide FA 72 Bazedoxifene 72 Shown Effective 72 INDICATED LOWER 72 Employment Inducement Awards 72 Projected Release Date 72 ORLive Presents 72 Novel Mechanism 72 Liprotamase 72 Announce Commencement 72 balsalazide disodium Capsules 72 Efficacy Trial 72 products MKC# PP 72 IMiDs ® 72 Regains Full 72 Osteoporosis Treatment 72 Signs Option Agreement 72 Ridaforolimus 72 Announce Early Termination 72 Panzem R 72 ALTROPANE R 72 Voluntarily Withdraws 72 Reports Receipt 72 Nasdaq IMGN 72 essential thrombocythemia ET 72 Multicenter Randomized 72 Controlled Trial 72 FDA Clearance 72 Anemia Drug 72 OTCBB FCSC 72 Systemic Sclerosis 72 Augment TM 72 Roche Boniva 72 Regenerative Cells 72 Subgroup Analysis 72 #-# Full Text 72 Anti Inflammatory 72 Novel Compounds 72 Regenerative Cell 72 diarrhea fatigue asthenia 72 submitted supplemental Biologics 72 Explore Strategic Alternatives 72 Breast Cancer Recurrence 72 Advanced Colorectal Cancer 72 IN PATIENTS WITH 72 Receptor Agonist 72 interferon beta 1a infertility 72 Secondary Hyperparathyroidism 72 See CLINICAL PHARMACOLOGY 72 Enzon Pharmaceuticals Inc 72 monoclonal antibody IgG1 Mab 72 Aloprim TM allopurinol sodium 72 FDA Panel Recommends 72 Placebo Controlled Trial 72 Shareholders Approve Acquisition 72 Prodarsan R 72 Drug Prevents 72 Combo Therapy 72 MKC# MKC# PP 72 Clinical Efficacy 72 Webcast Presentations 72 Obtains License 72 PEGylated Fab fragment 72 Unanimously Recommends Approval 72 5 FU leucovorin 72 liver resection surgeries 72 Aethlon Medical Releases 72 Rigel R# 72 Novel Treatments 72 Demonstrate Significant 72 Nasdaq DVAX 72 Amend Merger Agreement 72 TRIOLEX ™ 72 compound INCB# 72 ABLYNX 72 selective A2A adenosine receptor 72 Mouse Models 72 Net Loss Widens 72 arsenic trioxide injection 72 induced macular edema 72 Hormone Receptor Positive 72 Fentanyl Patch 72 Nasdaq MNKD focused 72 Announcement acc 72 Study Validates 72 Blood Thinner 72 Unfractionated Heparin 72 candidate AQ4N 72 evaluating satraplatin 72 Drug Coated Stent 72 NewsBite Downgrade Puts Pressure 72 Inflammatory Arthritis 72 Inks Licensing Deal 72 NASDAQ ADLR 72 Announce Collaboration 72 Improve Survival 72 Heart Failure Patients 72 Ltd Therapeutic Competitors 72 Completes Merger With 72 Clinical Outcome 72 UGNE 72 Pivotal Phase II 72 CHEAP ONLINE PHARMACY LOW 72 Successfully Completed 72 Provides Shareholder 72 Syncria R 72 2 inhibitor CYT# 72 FDA Approvable Letter 72 Relapsed Refractory 72 proprietary intravenous formulation 72 Increases Risk 72 Phase Ib IIa 72 CoTherix logo 72 researches develops licenses 72 Provides Guidance 72 FY# Loss Widens 72 Phase 2a Study 72 Viagra Soft Cialis Soft 72 MONSTERSTOX.COM Monsterstox.com 72 Announces Underwriters Exercise 72 HuCAL PLATINUM R 72 Using Dip Pen 72 FDA Approves Novel 72 nasal calcitonin product 72 gets USFDA nod 72 personalized cellular immunotherapy 72 PHASE III 72 Hemodialysis Patients 72 Drug Resistant 72 Bifunctional Muscarinic Antagonist Beta2 72 Horizant ™ 72 Antigen Specific 72 Inc. ProMetic www.prometic.com 72 Announces Effective Date 72 J Am Acad 72 induced mucositis 72 phase III isavuconazole 72 Nasdaq ACAD 72 Successfully Concludes 72 Dyax logo 72 Dementia Related Psychosis 71 Bullish Speculation 71 Patents Covering 71 Onyx Pharmaceuticals Announces 71 MSCRAMM ® 71 Naive Patients 71 Seliciclib CYC# 71 Myeloma Patients 71 Patients Undergoing 71 Bearish Average Crossover 71 please visit www.medicinova.com 71 NMT Medical Announces 71 Serostim ® 71 Maribavir 71 Inhibits 71 Inhibitor Human 71 palonosetron hydrochloride Injection Dacogen 71 GNSZ 71 myelodysplastic myeloproliferative diseases 71 submitted Biologics License 71 Receives Favorable Ruling 71 Vidaza R 71 Paris IPN Euronext 71 Inhalation Aerosol 71 Infected Patients 71 HuMax TAC 71 DOR BioPharma Announces 71 Receives Commitment 71 Paclitaxel Carboplatin 71 Atypical Antipsychotic 71 NeutroPhase TM 71 Oracea TM 71 Mutually Agree 71 please visit http:/www.supergen.com 71 Guides Inline 71 Gets Bearish Confirmation 71 Cardium Therapeutics TM 71 Oral Spray 71 Sirolimus Eluting Stent 71 Crowflight Announces 71 evaluating intravenous picoplatin 71 Metabolic Disorder 71 Reduces Pain 71 Antithrombin 71 Gene Mutation 71 PANVAC VF 71 SinuNase ™ 71 Vertex Pharmaceuticals Announces 71 Postmenopausal Women 71 Bush Embraces Pause 71 Kuvan R 71 Wins Patent Infringement 71 VEGFR2 inhibitor 71 CYP#A# CYP#D# 71 Phase IIa Trial 71 PROSTASCINT R 71 Canaccord Genuity Reiterates Buy 71 Salix Pharmaceuticals Announces 71 Inflammatory Disease 71 Study Shows Promise 71 Randomized Clinical Trial 71 Jointly Announce 71 Febuxostat 71 Desvenlafaxine 71 Atypical Hemolytic Uremic Syndrome 71 Soft Tissue Sarcoma 71 Upcoming Deadline 71 XPEL Announces 71 TNF Tumor Necrosis Factor 71 Seasonal Influenza Vaccine 71 Closes Second Tranche 71 Anthracycline 71 Idenix Novartis 71 NEBIDO VANTAS SUPPRELIN LA 71 Announce Receipt 71 Enters Into Collaboration 71 TRIOLEX HE# APOPTONE HE# 71 Reduced Risk 71 Vaccine Adjuvants 71 IMPDH inhibitor 71 Company website www.anormed.com 71 visit www.stemcellthera.com 71 Liver Toxicity 71 CybeRelease Decliners 71 Tumor Growth 71 Disease IBD 71 Reports Significantly Improved 71 Generic Version Of 71 Announces Postponement 71 visit www.sciclone.com 71 Adipose Derived Stem Cells 71 Multiple Sclerosis Rheumatoid Arthritis 71 Introduces Next Generation 71 Puts Purchased 71 Sirolimus Eluting 71 AstraZeneca PLC Arimidex 71 NASDAQ ENMD 71 Lifts FY# Outlook 71 Enteral Feed Devices 71 Advanced Renal Cell 71 Introduces Breakthrough 71 Acute Exacerbations 71 NASDAQ AVNR 71 Chronic Hepatitis B 71 Genes Linked 71 Announce Expiration 71 Ceflatonin R 71 Begin Clinical Trials 71 Univest Corporation Declares 71 include Phenoptin TM 71 ThermoDox R 71 Corp. AMEX CVM 71 Attracting Bullish Investors 71 Moving Average Crossover Alert

Back to home page